Obesity is a chronic disease associated with many complications. Weight loss of 5–15% can
improve many obesity-related complications. Despite the benefits of weight reduction, there …

Abstract Purpose of Review The burden of obesity worldwide is high and projected to rise.
Obesity increases the risk of several cardiovascular diseases and cardiometabolic risk …

The approval of once daily liraglutide, 3.0 mg, and once weekly semaglutide, 2.4 mg, for
chronic weight management provides a novel effective strategy against obesity. The reliable …

Background Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) have emerged as
promising therapeutic options for addressing Type‐2 diabetes, obesity, and related …

Clinical trials have investigated the weight loss effect of glucagon‐like peptide‐1 receptor
agonists (GLP‐1 RA) in adults with obesity without diabetes mellitus, but results for weight …

Obesity remains a major public health problem, affecting almost half of adults in the United
States. Increased risk of cardiovascular disease (CVD) and CVD mortality are major obesity …

Purpose Published data on the weight loss effects of glucagon-like peptide 1 (GLP-1)
receptor agonists are reviewed, with a focus on data from clinical trials. Summary Obesity is …

Background Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are new drugs for the
treatment of obesity. Objective To assess the weight-loss effects of GLP-1RAs in the …

Aim To determine the antiobesity effect and safety of glucagon-like peptide-1 receptor
agonist (GLP-1RA) including liraglutide, exenatide and semaglutide treatment in …

Over the past 30 years, there has been a dramatic rise in global obesity prevalence,
resulting in significant economic and social consequences. Attempts to develop …